Blue Lake Biotechnology shares positive data from RSV vaccine trial

[cafead]

via US-based biopharmaceutical company Blue Lake Biotechnology has reported positive preliminary data from the initial two cohorts of a Phase I/IIa study of BLB201, an investigational vaccine for severe respiratory syncytial virus (RSV) disease.

article source